共查询到1条相似文献，搜索用时 0 毫秒
1.
Summary. There are no reliable mean values of NG-monomethylarginine (NMMA) in blood and urine of patients with renal insufficiency available in the literature. Therefore
we investigate whether the NMMA levels are changed in blood and urinary excretion of nondialysed and dialysed patients with
chronic renal insufficiency to evaluate whether NMMA may reach sufficiently increased concentrations in blood of the patients
to exert toxic biological activity.
In nondialysed as well as in dialysed patients we find no significant difference in serum concentration of NMMA between patients
and controls. In nondialysed patients (all with a residual creatinine clearance lower than 15 ml/min), we find 94.5 ± 26.1 nM
(mean ± SD) versus 94.6 ± 19.5 nM in controls. Similar levels are found in serum of haemodialysed patients (each with serum
creatinine levels >700 μM): 83.0 ± 20.2 nM. The urinary excretion of NMMA in nondialysed patients is also not significantly different from the excretion
of controls: 123 ± 110 in patients versus 157 ± 117 nmol/24 hrs in controls. Furthermore, the clearance of NMMA is much lower
compared to the clearance of the dimethylarginine derivatives.
Based on the literature, the low nanomolar levels of NMMA found in blood of patients with renal insufficiency do not support
the statement that NMMA proper may act as a uremic toxin.
Received April 3, 2002 Accepted October 7, 2002 Published online January 20, 2003
Acknowledgements We thank the University of Antwerp, FWO (Fonds voor Wetenschappelijk Onderzoek) (G.0027.97 and G.0394.00), the Born-Bunge
Foundation, the OCMW Medical Research Foundation and Neurosearch Antwerp for the financial support.
Authors' address: Bart Marescau, Laboratory of Neurochemistry and Behaviour, UIA T504, University of Antwerp, Universiteitsplein 1, B-2610
Wilrijk, Belgium, Fax: 00 32 3 8202618; E-mail: bartold.marescau@ua.ac.be 相似文献